Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Inhibiting interleukin-6 in rheumatoid arthritis.

Literature DB >> 18817647

Inhibiting interleukin-6 in rheumatoid arthritis.

Abstract

Interleukin (IL)-6 is the most abundant proinflammatory cytokine in the circulation and synovial joints of patients with active rheumatoid arthritis. It has pivotal roles in the immune response and inflammation. In rheumatoid arthritis, it causes synovitis, joint destruction, and many systemic manifestations. Clinical trials of tocilizumab, a humanized anti-IL-6 receptor monoclonal antibody that blocks IL-6 signaling, have demonstrated therapeutic benefit. It heralds a new era of anticytokine therapy in rheumatoid arthritis.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2008 PMID： 18817647 DOI： 10.1007/s11926-008-0066-x

Source DB: PubMed Journal: Curr Rheumatol Rep ISSN： 1523-3774 Impact factor: 4.592

32 in total

1. Guidelines for the management of rheumatoid arthritis: 2002 Update.

Authors:
Journal: Arthritis Rheum Date: 2002-02

2. IL-6, LIF, and TNF-alpha regulation of GM-CSF inhibition of osteoclastogenesis in vitro.

Authors: Genevieve Gorny; Aubie Shaw; Merry Jo Oursler
Journal: Exp Cell Res Date: 2004-03-10 Impact factor: 3.905

3. Remodeling the pyramid or remodeling the paradigms concerning rheumatoid arthritis--lessons from Hodgkin's disease and coronary artery disease.

Authors: T Pincus; L F Callahan
Journal: J Rheumatol Date: 1990-12 Impact factor: 4.666

4. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors: Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal: Nature Date: 2006-04-30 Impact factor: 49.962

5. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation.

Authors: S Kotake; K Sato; K J Kim; N Takahashi; N Udagawa; I Nakamura; A Yamaguchi; T Kishimoto; T Suda; S Kashiwazaki
Journal: J Bone Miner Res Date: 1996-01 Impact factor: 6.741

6. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity.

Authors: R Madhok; A Crilly; J Watson; H A Capell
Journal: Ann Rheum Dis Date: 1993-03 Impact factor: 19.103

7. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

Authors: Josef S Smolen; Andre Beaulieu; Andrea Rubbert-Roth; Cesar Ramos-Remus; Josef Rovensky; Emma Alecock; Thasia Woodworth; Rieke Alten
Journal: Lancet Date: 2008-03-22 Impact factor: 79.321

8. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab.

Authors: Norihiro Nishimoto; Jun Hashimoto; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutomu Takeuchi; Norikazu Murata; Désirée van der Heijde; Tadamitsu Kishimoto
Journal: Ann Rheum Dis Date: 2007-05-07 Impact factor: 19.103

9. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.

Authors: Norihiro Nishimoto; Kazuyuki Yoshizaki; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutomu Takeuchi; Jun Hashimoto; Junichi Azuma; Tadamitsu Kishimoto
Journal: Arthritis Rheum Date: 2004-06

10. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.

Authors: Hideko Nakahara; Jian Song; Masamichi Sugimoto; Keisuke Hagihara; Tadamitsu Kishimoto; Kazuyuki Yoshizaki; Norihiro Nishimoto
Journal: Arthritis Rheum Date: 2003-06

6 in total

Inhibiting interleukin-6 in rheumatoid arthritis.

1. Guidelines for the management of rheumatoid arthritis: 2002 Update.

2. IL-6, LIF, and TNF-alpha regulation of GM-CSF inhibition of osteoclastogenesis in vitro.

3. Remodeling the pyramid or remodeling the paradigms concerning rheumatoid arthritis--lessons from Hodgkin's disease and coronary artery disease.

4. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

5. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation.

6. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity.

7. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

8. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab.

9. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.

10. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.

1. Anti-interleukin 6: first line in rheumatoid arthritis?

2. [Recommendations of the German rheumatology society on the use of tocilizumab in rheumatoid arthritis].

Review 3. Prevention of colitis-associated cancer: natural compounds that target the IL-6 soluble receptor.

4. Sex differences in systemic bone and muscle loss following femur fracture in mice.

Review 5. Identification and manipulation of tumor associated macrophages in human cancers.

Review 6. Recent advances in neutralizing the IL-6 pathway in arthritis.